Mechanisms of resistance to EGFR tyrosine kinase inhibitors

• Glavni autori: Lihua Huang (Autor), Liwu Fu (Autor)
• Format: Knjiga
• Izdano: Elsevier, 2015-09-01T00:00:00Z.
• Teme: article
• Online pristup: Connect to this object online.

Since the discovery that non-small cell lung cancer (NSCLC) is driven by epidermal growth factor receptor (EGFR) mutations, the EGFR tyrosine kinase inhibitors (EGFR-TKIs, e.g., gefitinib and elrotinib) have been effectively used for clinical treatment. However, patients eventually develop drug resi...